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of patients with end-stage renal disease (ESRD) are reported to have cardiovascular disease. This observation has
enormous clinical relevance because the leading causes of death for patients with ESRD are of cardiovascular
disease etiology, including heart failure, myocardial infarction, and sudden cardiac death. The 2 systems most
commonly used to classify the severity of heart failure are the New York Heart Association (NYHA) functional
classiﬁcation and the American Heart Association (AHA)/American College of Cardiology (ACC) staging system. With
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sodium and water. Thus, by deﬁnition, nearly all patients with ESRD develop a symptomatology consistent with heart
failure if ﬂuid removal by RRT is delayed. Neither the AHA/ACC heart failure staging nor the NYHA functional
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whether evaluation occurs before or after ﬂuid removal by RRT. Consequently, the incidence, severity, and outcomes
of heart failure in patients with ESRD are poorly characterized. The 11th Acute Dialysis Quality Initiative has
identiﬁed this issue as a critical unmet need for the proper evaluation and treatment of heart failure in patients with
ESRD. We propose a classiﬁcation schema based on patient-reported dyspnea assessed both pre- and post-
ultraﬁltration, in conjunction with echocardiography. (J Am Coll Cardiol 2014;63:1246–52) ª 2014 by the
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1247cardiovascular disease, including heart failure, myocardial
infarction, and sudden cardiac death (3,5–7).
In CKD, and particularly ESRD, 3 major mechanisms
induce and exacerbate cardiomyopathy: volume overload,
pressure overload, and nonhemodynamic factors associated
with CKD. The nonhemodynamic factors are manifold, and
include activation of the renin-angiotensin system, catalytic
iron-dependent oxidative stress, inﬂammation, and stimulation
of proﬁbrogenic factors (5,7) These pathological mechanisms
cause direct and immediate effects and affect long-term disease
progression in these patients (5,7).
The American Heart Association (AHA), American
College of Cardiology (ACC), and European Society of
Cardiology (ESC) have developed guidelines recommending
that heart failure be classiﬁed in a manner that reﬂects its
risk factors, severity, and natural history (2,8,9). In the
AHA/ACC guidelines, stage C heart failure deﬁnes patients
with current or prior symptoms of heart failure. The primary
form of maintenance renal replacement therapy (RRT)
worldwide is hemodialysis, and a smaller proportion of pa-
tients use peritoneal dialysis. With rare exceptions, lack of
ﬂuid removal by RRT in patients undergoing dialysis leads
to dyspnea and congestion due to salt and water retention.
Thus, by deﬁnition, all patients undergoing dialysis, even
those with no structural heart disease, experience New York
Heart Association (NYHA) functional class (FC) III to IV
symptoms if ﬂuid removal by RRT is delayed. Thus, man-
agement and treatment of patients undergoing dialysis with
heart failure is difﬁcult due to the dynamic nature of ﬂuid
overload.
A “real world” example is illustrated by the following
clinical vignette: a patient undergoing dialysis is referred
to the cardiologist because of worsening heart failure
symptoms. Because of transport to and from the dialysis
clinic in addition to the time required for dialysis, which
usually exceeds 6 h, patients on dialysis rarely schedule non-
nephrology doctor’s visits on the same day as dialysis ses-
sions. Thus, visits to the cardiologist almost always occur
prior to a dialysis day. During the visit, the cardiologist
correctly identiﬁes ﬂuid overload, and the patient is likely to
be returned to the nephrologist for “better” dialysis and more
ultraﬁltration. This is problematic because the nephrologist
likely sent the patient to the cardiologist because the patient
was already receiving the maximal tolerable ultraﬁltration.
The incidence, severity, and outcomes of heart failure in
patients undergoing dialysis are poorly characterized and
potentially undertreated, because the severity of symptoms
relative to the frequent changes in volume status occurring
before and after RRT are not witnessed and remain poorly
documented (5,7). In addition, none of the existing practice
guidelines for the treatment of ﬂuid overload in patients on
dialysis comment on whether it is appropriate to apply the
AHA/ACC/ESC stages of heart failure or the NYHA FC
system (10).
For advancement in the treatment of heart failure in patients
on dialysis, a methodology that improves the characterizationof heart failure in these patients is
essential and urgently required.
The implementation of classiﬁca-
tion systems for any disease syn-
drome can have a positive impact
on disease management (10–12).
For example, introduction of the
CKDstaging systemand theRisk,
Injury, Failure, Loss, End-stage
renal disease (RIFLE) (11,12)
staging system for acute kidney
injury have allowed clinical in-
vestigators to better characterize
disease processes, conduct epide-
miological studies, guide clinical
trial enrollment, standardize prac-
tice guidelines, and improve
clinicians’ ability to track disease
progression (13,14).
The 11th Acute DialysisQuality Initiative (ADQI) meeting was convened to focus
on cardiorenal syndrome (15). The working group that
focused on cardiorenal syndrome type IV (advanced CKD
and progressive heart disease) identiﬁed this clinical and
research issue as a critical unmet need in the care of patients
on dialysis with heart failure. We based this assessment on
the fact that accurate risk stratiﬁcation of patients with any
given disease state is essential to improve clinical status and
outcomes.
Workgroup Methodology
The speciﬁc methods for the ADQI conferences were
developed and reﬁned over the ﬁrst 4 international confer-
ences (16). Brieﬂy, our methods comprise: 1) a systematic
search for evidence, with review and evaluation of the
available literature; 2) establishment of clinical and physio-
logical outcomes and of measures to be used for treatment
comparisons; 3) description of current practice and the
rationale for use of current techniques; and 4) analysis of
areas in which evidence is lacking and future research is
required to obtain new information. The topics chosen for
each conference are selected on the basis of the following
criteria: 1) prevalence of the clinical problem; 2) estimates
of variation in clinical practice; 3) potential inﬂuence
on outcome; 4) potential for development of evidence-based
guidelines; and 5) availability of scientiﬁc evidence. A
detailed report of the ADQI process has been published
previously (16).
Before the conference and according to the structure of
previous ADQI consensus meetings, we performed a sys-
tematic review of the literature (11,17). Speciﬁcally, we used
the search terms “heart failure,” “peritoneal dialysis,” “he-
modialysis,” “renal replacement therapy,” “chronic kidney
disease,” “dialysis,” “guidelines,” “consensus,” and “end-stage
renal/kidney disease,” combined with “prognosis,” “major
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“stroke,” “volume overload,” “ﬂuid overload,” “sudden car-
diac death,” “death,” and “mortality.” In view of the volume
of retrieved literature, only representative publications are
cited in this proposal. Furthermore, we opted to base our
staging proposal on clinical scenarios for which data are
ample. We also excluded the speciﬁc clinical situations
pertaining to renal or heart transplant or to mechanical
circulatory support.
Based on the literature identiﬁed prior to the conference,
the following key questions were considered:
1. Are there current heart failure staging systems that can
be applied speciﬁcally to patients undergoing dialysis?
2. What are the critical features of a staging system that
can be easily used by clinicians to establish appropriate
diagnostic and therapeutic approaches?
3. How can a new heart failure staging system speciﬁcally
address the unique nature of nonphysiological periodic
volume removal, which characterizes all forms of
dialysis?Current Staging Systems of Heart Failure
Multiple heart failure staging systems and classiﬁcation
schemes have been proposed. In 1977, Wagner and Cohn
(18) proposed a classiﬁcation system based on 3 broad
pathophysiological mechanisms: systolic dysfunction, dia-
stolic dysfunction, and volume overload. These 3 conceptual
etiologies remain relevant in the current assessment and
treatment of heart failure. Since 2005, the ESC/ACC/AHA
have developed consensus guidelines that include a staging
system for heart failure to reﬂect its severity as well as its
natural history (2). However, the most commonly used
system to characterize the severity of heart failure symptoms
is the NYHA FC (10) (Table 1), which is based on a
grading of dyspnea relative to the intensity of physical ac-
tivity. The ESC/ACC/AHA and NYHA classiﬁcation
systems have proven to be robust and have been used suc-
cessfully to assess the epidemiology and severity of heartTable 1 New York Heart Association Function Classiﬁcation
Class Patient Symptoms
Class I (mild) No limitation of physical activity. Ordinary physical
activity does not cause undue fatigue, palpitation,
or dyspnea.
Class II (mild) Slight limitation of physical activity. Comfortable at rest,
but ordinary physical activity results in fatigue,
palpitation, or dyspnea.
Class III (moderate) Marked limitation of physical activity. Comfortable at
rest, but less than ordinary activity causes fatigue,
palpitation, or dyspnea.
Class IV (severe) Unable to carry out any physical activity without
discomfort. Symptoms of cardiac insufﬁciency
at rest. If any physical activity is undertaken,
discomfort is increased.
Data from the Criteria Committee of the New York Heart Association (10).failure. They have been the basis for establishing inclusion
criteria and response to therapy in seminal clinical trials
conducted in patients with heart failure (19–21).
However, neither of these staging systems can be used in
their current forms to assess the severity of heart failure
in patients on dialysis because dyspnea in these patients is
not solely attributable to heart failure and its severity changes
in relation to the timing of volume removal. For nearly all
patients undergoing dialysis, delay in or absence of RRT
results in dyspnea due to ﬂuid overload even if the patient’s
heart is structurally normal. Thus, all patients on dialysis can
theoretically be considered in NYHA FC III to IV, which
can improve to NYHA FC I after ﬂuid removal. In patients
not on dialysis with acutely decompensated heart failure,
euvolemia can be restored and maintained for variable pe-
riods of time with appropriate medical therapies; however,
all patients undergoing dialysis begin to retain salt and water
immediately after RRT treatment, and accumulation con-
tinues until the next prescribed RRT (this occurs in both
peritoneal dialysis and hemodialysis to varying degrees).
We concluded that a staging system for heart failure in
patients on dialysis must be able to deﬁne heart failure
symptoms in relation to the response to the periodic non-
physiological volume removal that occurs with all forms of
dialysis. Thus, the timing of assessment and the periodicity
of dialysis must be taken into account. In addition, we
sought to develop a patient-centered staging system that was
easily understandable by care providers and therefore easily
usable for planning further diagnostic evaluations and
treatment for patients with coexisting heart failure and
dialysis-requiring ESRD.
Proposed Staging System
We considered a number of possible solutions to the
problem outlined in the previous text. To speciﬁcally
exclude patients with normal hearts on dialysis, the pro-
posed classiﬁcation system incorporates echocardiographic
criteria that indicate the presence of underlying structural
heart disease. We modiﬁed the NYHA FC of dyspnea
severity into a new system with a description of heart failure
symptoms and their response to ﬂuid removal by RRT/
ultraﬁltration. The 3 elements of our proposed staging
schema are as follows:
1. Standardized echocardiographic evidence of structural
and/or functional heart abnormalities;
2. Dyspnea occurring in the absence of primary lung
disease, including isolated pulmonary hypertension;
and
3. Response of congestive symptoms to RRT/ultraﬁltration.
The standardized echocardiographic criteria are based
on the evidence of mild to moderate echocardiographic
disease cutoffs that are detailed in the American Association
of Echocardiography consensus guidelines (which are
consistent with the European Society of Echocardiography
Table 2 Echocardiography Criteria*
LVH (LV mass index >110 g/m2 for women and >130 g/m2 for men or
>47 g/m2.7 for women and >50 g/m2.7 for men). Latter measure is
LV mass calculated by the area-length method and indexed to height
(22,38,39).
Increased LV volume index >86 ml/m2 diastolic or >37 ml/m2 systolic.
Left atrial enlargement (left atrial volume index 34 ml/m2).
Diastolic dysfunction (ASE grade 2).
Moderate to severe mitral or aortic valvular disease (stenosis or regurgitation).
RV systolic dysfunction by accepted criteria (e.g., TAPSE <17 mm).
LV ejection fraction 45%.
Regional wall motion abnormality of LV (>10% of the myocardium).
*At least 1 (of 8) listed criteria must be abnormal to fulﬁll the deﬁnition of echocardiographic
evidence of heart disease.
LV ¼ left ventricle; LVH ¼ left ventricular hypertrophy; RV ¼ right ventricle; TAPSE ¼ tricuspid
annular plane systolic excursion.
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suggest or are supportive of cardiac disease are summarized
in Table 2.
The classiﬁcation system that we propose is summarized
in Figure 1.
Patients who present with severe dyspnea that is relieved
by RRT/ultraﬁltration are categorized by their post-therapy
status. For example, a patient with echocardiographic evi-
dence of left ventricular hypertrophy who presents to the
dialysis clinic with dyspnea at rest, undergoes RRT, andFigure 1 ADQI Heart Failure in ESRD Classiﬁcation System
Classiﬁcation is determined by a dyspnea assessment before and after renal replacemen
before and after RRT/UF, they are scored by their post-treatment assessment. The class
achievement of optimized UF and is representative of the patient’s usual level of dyspnea
would be classiﬁed as class 2R. zIf dyspnea symptoms improve to class II levels, the pa
ESRD ¼ end-stage renal disease; NYHA ¼ New York Heart Association.then experiences no symptoms would be classiﬁed as ADQI
class 2R. In addition, the RRT/ultraﬁltration metric does
not necessarily suggest a single therapy. Symptomology
relieved by RRT/ultraﬁltration assumes that the patient is
receiving RRT at the appropriate frequency.
Strengths and limitations. Like previously published
staging systems, the proposed classiﬁcation system will
require prospective testing and validation in appropriate
patient cohorts. In addition, because echocardiographic
ﬁndings are a prerequisite for entry into the classiﬁcation
system, standardization of the collection and documentation
of these echocardiographic data is imperative.
Studies in patients undergoing dialysis that deployed
continuous hemodynamic monitoring before, during, and
after RRT with ultraﬁltration have demonstrated that inter-
dialytic volume accumulation results in increased pressures in
the pulmonary artery and right ventricle (Fig. 2) (24,25). The
proposed staging system accommodates the “tidal nature” of
nonphysiological volume removal. Another strength of this
proposed system is that symptom grading is similar to grading
in other heart failure symptom scales (e.g., the NYHA FC
system) that are familiar to clinicians. In addition, the pro-
posed staging system is based on patient-reported sympto-
mology and is thus patient centered.
Patients with heart failure on dialysis pose unique diag-
nostic and therapeutic challenges; for example, a patientt therapy (RRT)/ultraﬁltration (UF). When patients have the same class assessment
iﬁcation scheme assumes that the class assignment represents the patient’s
before and after RRT/UF. *If dyspnea symptoms improve to class I levels, the patient
tient would be classiﬁed as class 3R. ADQI ¼ Acute Dialysis Quality Initiative;
Figure 2 Changes in Right Heart Pressures Over 8 Days in Patients Undergoing Hemodialysis
Eight-day continuous hemodynamic trend from a patient who underwent thrice-weekly hemodialysis (HD). A marked reduction in right ventricular systolic pressure (RVSP) and
right ventricular diastolic pressure (RVDP), as well as estimated pulmonary artery diastolic (ePAD) pressure, was seen during each dialysis session, followed by progressive
pressure increments until the next dialysis session. The most marked increase in cardiac pressures was seen the day after a weekend (i.e., an extra day without dialysis). The
solid line shows the median value, and the shaded areas are the range (6th and 94th percentiles). HD procedures are indicated at the top of the graph. bpm ¼ beats/min.
(Permission pending.)
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who becomes dyspneic may be deemed to have ﬂuid over-
load and referred back to the nephrologist for standard
thrice-weekly hemodialysis and additional ultraﬁltration.
Thus, RRT is a form of treatment for ESRD with heart
failure. However, in some cases, this therapy fails to improve
or resolve the symptoms of dyspnea. This clinical scenario
raises multiple questions regarding presence and severity
of heart failure, type of monitoring required, and therapeutic
approaches needed to treat the persistent symptoms. A
validated classiﬁcation system would prove useful here and
could potentially be useful for uniform assessment of heart
failure in patients undergoing dialysis. In addition, surveil-
lance of these patients will allow better understanding of the
temporal aspects of heart failure and ESRD. Speciﬁcally,
does heart failure usually precede ESRD, is it the reverse, or
is this a cardiorenal interaction?
Validation of the proposed system would start with
classiﬁcation of a large cohort of patients undergoing
dialysis. The initial assessment would include collection and
documentation of appropriate echocardiographic data.
Echocardiography is recommended for all patients on
dialysis within 1 to 3 months of starting RRT (5,7). In
addition, patients would be queried about the presence of
dyspnea pre- and post-RRT/ultraﬁltration. Simple tools
such as the Likert scale and visual analogue scale have been
shown to be useful in the assessment of dyspnea in patients
with heart failure and could be used as appropriate (26,27).
Assessment of patient symptoms pre- and post-RRT isroutine and considered standard of care. However, these
data may not always be gathered in standard database data
ﬁelds, and standardization may be required. Once the
prevalence of the various stages of the new classiﬁcation
system is determined, follow-up to assess outcomes would
be needed. Our operating hypothesis is that mortality risk
would increase through each of the proposed stages. After
initial longitudinal assessment, the proposed staging system
might be useful for clinical trial entry and design. For
example, does more frequent hemodialysis improve ADQI
class function? Are outcomes for patients with advanced
heart failure and ESRD improved with peritoneal dialysis
versus hemodialysis? In addition, certain standard heart
failure medications (e.g., angiotensin-converting enzyme
inhibitors, angiotensin II receptor blockers, beta-blockers)
might be better suited for certain ADQI heart failure
stages than for others. Recent data suggest that treating
patients with ESRD with spironolactone may improve
structural heart disease and improve survival, and the pro-
posed classiﬁcation schema should be deployed in
conjunction with future studies of aldosterone blockade in
patients with ESRD (28,29).
In addition to future research concerning the descriptive
epidemiology and prognosis of patients on dialysis classi-
ﬁed with this new scheme, future studies may use novel
technologies such as advanced imaging and biomarkers to
aid in support of the classiﬁcation or in the traditional
domains of testing (screening, diagnosis, prognosis, and
management) (30,31).
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Important therapies for patients with heart failure on dialysis
may include more frequent hemodialysis, preference for
peritoneal dialysis, or polyelectrolytes that remove sodium
via the gut (32). For patients who are dyspneic even with
good volume control, standard heart failure therapies may
require additional adjustments. However, before treatment
advances can be made, it is essential to be able to differen-
tiate patients with ﬂuid overload alone in the absence of
structural heart disease from patients in whom ﬂuid overload
and dyspnea can be directly attributed to underlying cardiac
disease.
The precise criteria that deﬁne echocardiographic evi-
dence of structural heart disease are an important component
of any proposed classiﬁcation, speciﬁcally, the differentiation
of heart failure with preserved ejection fraction versus vol-
ume overload alone. Both clinical entities can present with
clinical and echocardiographic features of “diastolic dysfunc-
tion.” For the subset of patients in whom this distinction is
required, we propose a diagnostic pathway to ascertain the
correct diagnosis (Online Appendix). The distinction can
be particularly important in patients undergoing dialysis
due to the high prevalence of left ventricular hypertrophy.
Schwartzenberg et al. (33) demonstrated that 35% of pa-
tients with heart failure with preserved ejection fraction,
despite elevated left ventricular end-diastolic pressure values,
experienced a drop in stroke volume with intravenous nitro-
prusside. This appears to be due to excessive reduction in
ﬁlling pressure and thus ﬁlling volume (end-diastolic volume)
due to diastolic dysfunction. Many patients on dialysis would
be expected to experience something similar with volume
removal during RRT.
The dynamic assessment (i.e., before and after ultraﬁltra-
tion) is particularly important given that asymptomatic dia-
stolic dysfunction is prevalent in the community and may
be more prevalent in the ESRD population (34). As sug-
gested in the Kidney Disease: Improving Global Outcomes
consensus guideline, echocardiography should be performed
in all incident patients on dialysis (5). Novel and known
cardiac biomarkers, along with dynamic exercise testing, may
also be useful in identifying important subgroups (35).
More invasive hemodynamic monitoring may be of beneﬁt
for some patients and for research purposes (24). In the
development of a new classiﬁcation schema, the epidemi-
ology and phenotype of this population should be well
characterized. Other important considerations include the
standardization of dyspnea assessment and timing of echo-
cardiographic assessment (36).
At the end of 2010, the patient population on dialysis was
more than 300,000 in Europe and 414,000 in the United
States; these numbers are projected to increase as the pop-
ulation ages (37). Patients undergoing dialysis are charac-
terized by a tremendous burden of structural heart disease
and are uniquely susceptible to the consequences of non-
physiological changes in volume status (5). Therefore, thestandardization of heart failure diagnosis, prognosis, and
treatment is an urgent concern for these patients and for the
clinicians charged with delivery of their medical care.
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APPENDIX
For a complete list of the ADQI Consensus Group members, as well as
supplemental information, please see the online version of this article.
